

Fabrizio VA, Boelens JJ, Mauguen A, et al. Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy. *Blood Adv.* 2022;6(7):1961-1968.

The model that the authors used to calculate fludarabine pharmacokinetics was based on a different article than what was cited as reference 19 on page 1962 under “Outcomes of interest.” Therefore, reference 19 on page 1968 should read as follows:

19. Ivaturi V, Dvorak CC, Chan D, et al. Pharmacokinetics and model-based dosing to optimize fludarabine therapy in pediatric hematopoietic cell transplant recipients. *Biol Blood Marrow Transplant.* 2017;23(10):1701-1713.

<https://doi.org/10.1182/bloodadvances.2023010269>

© 2023 by The American Society of Hematology. Licensed under [Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International \(CC BY-NC-ND 4.0\)](https://creativecommons.org/licenses/by-nc-nd/4.0/), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.